#United States #Washington, D.C. #Rare Diseases #LGMD #Speak Foundation

Advocates Unite on Capitol Hill to Urge Support for LGMD Community

This past week, a dedicated group of advocates representing patients with limb-girdle muscular dystrophy (LGMD) traveled from over 20 states to Washington, D.C. Their mission was straightforward yet critical: to bring awareness to the challenges faced by those living with LGMD and to press lawmakers for necessary changes in policies surrounding rare disease research and treatment development.

Limb-girdle muscular dystrophy encompasses a variety of rare genetic conditions that lead to progressive muscle weakness. Currently, there is no FDA-approved treatment for any subtype of LGMD, despite significant advancements in scientific research. The advocates hope to change that.

During this pivotal event known as LGMD Day on the Hill, advocates participated in over 60 meetings with congressional offices, urging officials to enhance federal investment in LGMD research, increase access to Department of Defense funding, and establish clearer regulatory pathways for treatments aimed at rare diseases. The discussions were not only productive but also deeply personal, as many attendees shared their own experiences living with this debilitating condition.

Kathryn Bryant Knudson, CEO and founder of The Speak Foundation, who herself lives with LGMD, highlighted the urgency of their advocacy. “Time is measured differently for individuals with progressive rare diseases. As we wait for research and clinical trials to unfold, we continuously risk losing strength,” she stated passionately. Her perspective as a patient underscores the importance of including voices from the community in decision-making processes regarding treatment and research priorities.

The advocates emphasized the necessity for Congress to support policies that acknowledge both the unique challenges of researching rare diseases and the vital insights that patients provide. They called for more inclusive engagement at the early stages of clinical trials, allowing patient perspectives to shape essential elements like eligibility criteria and outcomes that are relevant to everyday life.

Moreover, discussions included a pressing need for greater regulatory clarity. Often, rare disease development initiatives suffer from inconsistent funding and regulatory expectations. When guidelines shift unpredictably during the development process, potential breakthroughs can stall, leading to lost investments and delayed patient access to new therapies.

As part of the day’s activities, The Speak Foundation honored two congressional champions of LGMD: Rep. John Joyce (R-PA) and Rep. Jake Auchincloss (D-MA). Both of these legislators play pivotal roles in committees that influence health policy. Rep. Joyce, a physician, has been an advocate for sustaining incentives for the development of rare disease treatments through his work on the ORPHAN Cures Act. Meanwhile, Rep. Auchincloss has made strides in modernizing clinical research and making trials more accessible to patients.

The acknowledgment of these champions brought a sense of hope to the advocates. “Hearing directly from individuals living with rare diseases like LGMD illustrates the real-world implications of our work,” commented Rep. Joyce. He highlighted the necessity of maintaining momentum in research funding to ensure that patients receive the care they desperately need.

As the LGMD community moves forward, the advocacy efforts stress a significant truth: progress in medical innovation matters only when it reaches those who stand to benefit from it. “We are entering a new era for LGMD,” Knudson concluded. “Now we need our policies to keep pace with scientific advancements.”

The Speak Foundation, established in 2008, is a nonprofit organization dedicated to advocating for individuals with LGMD. It creates a platform for patients to collaborate with healthcare professionals, researchers, and policymakers to drive meaningful change in care and treatment. Through their ongoing initiatives, the Speak Foundation aims to empower patients and families, ensuring they have a direct hand in shaping the future of LGMD research and treatments.